Journals / Ankara Üniversitesi Tıp Fakültesi Mecmuası / 2017 / Cilt: 70 - Sayı: 2

What do Patients Know About Pneumococcal Vaccine?

Hastalarımız Pnömokok Asısını Biliyor Mu?

Pages
91–96
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The rate of vaccination increased with increasing age (OR, 2.71; CI, 1.09-5.22; p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Despite its proven efficacy, the rate of antipneumococcal vaccination remains considerably low.
📊
Key Findings & Data:Determination of factors affecting vaccination behavior may contribute to efforts aimed at boosting vaccination rates.
💡
Conclusion & Impact:The rate of vaccination increased with increasing age (OR, 2.71; CI, 1.09-5.22; p
🔬Design:Survey & Empirical Study
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: Despite its proven efficacy, the rate of antipneumococcal vaccination remains considerably low. Determination of factors affecting vaccination behavior may contribute to efforts aimed at boosting vaccination rates. We therefore aimed to investigate the anti-pneumococcal vaccination rates and potential factors affecting vaccination behavior among patients presenting to chest disease department. Material and Method: A written questionnaire was applied to all patients who presented to Chest Diseases Department between October 2011 and January 2012. Results: A total of 1251 patients (671 women, 580 men) were enrolled. Among 766 participants who had any indication for anti-pneumococcal vaccination, 9.9% stated that they had been vaccinated. The rate of vaccination increased with increasing age (OR, 2.71; CI, 1.09-5.22; p

Özet

Amaç: Günümüzde etkinliği kanıtlanmasına rağmen pnömokok asısıyla asılanma oranının oldukça düsük olduğunu görüyoruz. Asılanma davranısını etkileyen faktörlerin aydınlatılması asılanmayı arttırmak için çözüm yollarına ısık tutabilir. Bu amaçla hastaların pnömokok asısı ile asılanma oranları ve asılanma davranısını etkileyen faktörler değerlendirildi. Gereç ve Yöntem: Ekim 2011 ve Ocak 2012 tarihleri arasında Göğüs Hastalıkları polikliniğine basvuran tüm hastalara yazılı bir anket uygulandı. Bulgular: Polikliniğe basvuran 1251 (671 kadın, 580 erkek) hasta arastırmaya dahil oldu. Pnömokok asısı endikasyonu olan 766 hastanın %9.9' u asılandığını belirtti. Yasın artması ile asılanma oranı artıyordu. (OR, 2,71; CI, 1,09-5,22; p

🔖

Cite This Article

KAYACAN, O., ÇİFTCİ, F., SEN, E., DEMİR, N. (2022). What do Patients Know About Pneumococcal Vaccine?. Ankara Üniversitesi Tıp Fakültesi Mecmuası, Cilt: 70 - Sayı: 2, 91–96. https://ajindex.com/articles/443694

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Centers for Disease Control and Prevention. CDC framework for preventing infectious diseases. Sustaining the Essentials and Innovating for the Future, Atlanta, Georgia, 2011. Available at:
  2. Janoff EN, Musher DM. Streptococcus pneumonia In: Bennet JE, Dolin R, Blaser MJ., editors. Principles and Practice of Infectious Diseases. 8th ed. Philadelphia: Elsevier, 2015:2310-2327
  3. Drijkoningen J, Rohde GGU. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect 2014; 20: 45-51 4. Recommended Adult Immunization Schedule. United States-2016. Available from: http://www.cdc.gov/vaccines/schedules/ downloads/adult/adult-combined schedule. pdf
  4. Birinci Basamak Sağlık Hizmetlerinde Çalışan Hekimler için Yaşlı Sağlığı Tanı ve Tedavi Rehberi 2010. Sağlık Bakanlığı Temel Sağlık Hizmetleri Genel Müdürlüğü. Available from: http://sbu.saglik.gov.tr/ Ekutuphane/ kitaplar/t3.pdf 6. Centers for Disease Control and Prevention. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged >=65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. September 19, 2014 / 63(37);822-825. Available from:
  5. Domínguez A, Izquierdo C, Salleras L, Ruiz L, Sousa D, et al. Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly. Eur Resp J 2010; 36:608-614
  6. Naito T, Matsuda N, Tanei M, et al. Relationship between public subsidies and vaccination rates with the 23-valent pneumococcal vaccine in elderly persons, including the influence of the free vaccination campaign after the great East Japan earthquake J Infect Chemother 2014;20: 450-453
  7. Poethko-Müller C, Schmitz R. Vaccination coverage in German adults: results of the German health interview and examination survey for adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013; 56: 845-857
  8. Aka Aktürk Ü, Görek Dilektaşlı A, Şengül A, et al. Influenza and pneumonia vaccination rates and factors affecting vaccination among patients with chronic obstructive pulmonary disease. Balkan Med J 2017;34:206-211
  9. Alici DE, Sayiner A, Unal S.Barriers to adult immunization and solutions: Personalized approaches. Hum Vaccin Immunother 2017;13:213-215
  10. Özsu S, Uçar E, Arslan Y, ve ark. The frequency of influenza and pneumococcal vaccination in COPD. Solunum 2011; 13:21-25
  11. Erer OF, Karadeniz G, Gazibaba D, ve ark.